In the Media - Optellum

We use cookies to optimize our website and our service.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Biopharma AI Collaborations Driving Innovative Change in Drug Development

Biopharma AI Collaborations Driving Innovative Change in Drug Development

J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ tech

J&J teams up with Optellum to improve lung cancer survival rates

Optellum collaborating with J&J

Optellum, Johnson & Johnson Collaborate on AI-Powered Lung-Health Initiative

Optellum Joins J&J’s Lung Cancer Initiative

Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment

EIT Health-supported Optellum partners with J&J

Emintera: Optellum announces strategic collaboration with Johnson & Johnson’s Lung Cancer Initiative to apply AI to transform early lung cancer treatment

Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment

First Edition: Aug. 19, 2021